The Rage to Consolidate in Diagnostics
Executive Summary
As diagnostic industry infrastructure and R&D costs escalate and buyers gain more clout, manufacturers are looking to consolidation for long-term viability and growth. Faster growth is the motivation for market leaders, while size and operating efficiencies are driving other deals.
You may also be interested in...
With Pluck and Luck, Sysmex Tackles Hematology
Sysmex's break in the US with distribution partner Roche frees it to reap the rewards of building its own brand. It's betting that a best-of-breed strategy can help it double revenues by 2006 and increase margins. It's got a stellar reputation but it's in a tough market that doesn't leave much room for error.
With Pluck and Luck, Sysmex Tackles Hematology
Sysmex's break in the US with distribution partner Roche frees it to reap the rewards of building its own brand. It's betting that a best-of-breed strategy can help it double revenues by 2006 and increase margins. It's got a stellar reputation but it's in a tough market that doesn't leave much room for error.
Sysmex Bets on Best of Breed
Sysmex Corp. of America and Roche Diagnostics are ending their four-year-old hematology alliance a year early. Both companies say the alliance has been successful. But Roche wants to focus on its franchises in fast-growing segments of the laboratory, and Sysmex, with a series of hematology product introductions underway, wants to raise its profile in the US. The move also signals an about-face from the initial premise for doing the deal, one which was widely pervasive throughout the medical device and diagnostics sectors in the 1990s: that customers want one-stop shopping and the discounts that come from bundling one manufacturer's broad product lines. Sysmex instead is turning to a best-of-breed strategy, which has served it well in major European markets, and which, it believes, will ultimately be more lucrative.